Indian trial reform on the way, but does it make sense?

India is proceeding with its plan to reform how sponsors and CROs pay compensation to patients, but the draft guidance contains some confusing wording that has troubled the industry. As Outsourcing-Pharma reports, the proposed guidelines say trial runners must pay patients if the tested drug fails "to provide intended therapeutic effect," which the industry points out goes against the very purpose of conducting a clinical trial. Some in the CRO business believe the government will eventually amend the language, but the process could take time. Report

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.